| Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus. | |
| | |
MedLine Citation:
|
PMID: 22025849 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by insulin deficiency or resistance. Management starts with single oral antidiabetic drug (OAD) but eventually switch over to combination therapy because of progressive β-cell dysfunction. Hypoglycemia, weight gain, and adverse cardiovascular events are major limitations of the available OADs (Sulfonylureas [SUs], thiazolidinediones [TZDs]). Saxagliptin, a reversible, competitive dipeptidyl peptidase-4 inhibitor, is recently approved agent in the treatment of T2DM. It acts by preventing the degradation of glucagon-like peptide - 1 and hence increases secretion of insulin and decreases secretion of glucagon. It is a well-tolerated agent with commonly reported adverse events which include upper respiratory tract infection, urinary tract infection, and headache. Hypoglycemia, weight gain, and adverse cardiovascular events are negligible as compared with other OADs. In clinical studies, saxagliptin was found to be effective and well tolerated when used as a monotherapy as well as in combination with metformin, SUs and TZDs. It is administered in the dose range of 2.5 to 5 mg once a day regardless of meal. Dosage reduction is required in patients having moderate to severe renal impairment as well as with concurrent administration of strong CYP3A4/5 inhibitors. To conclude, saxagliptin because of its novel mechanism of action (preserving beta cell function) and better tolerability profile seems to be a promising agent in the treatment of T2DM, especially in the early stage of the disease, but long-term clinical studies are required to prove its status in the management of T2DM. |
| | |
Authors:
|
Darshan J Dave |
Related Documents
:
|
22022539 - Cost-effectiveness of angiotensin-converting enzyme inhibitors for the prevention of di... 15013019 - The development of potent non-peptidic ptp-1b inhibitors. 3929599 - Effects of oral sulfonylureas on the spectrum of defects in non-insulin-dependent diabe... 6470179 - Influence of glycaemic normalisation by an artificial pancreas on phagocytic and bacter... 2650739 - Electric charge distribution in proteins and ionic strength dependence of reaction rate. 8605079 - Selected metals status in patients with noninsulin-dependent diabetes mellitus. 8310709 - Preferential elimination of pivalate with supplemental carnitine via formation of pival... 20167159 - Impaired fasting glucose and the metabolic syndrome in an indigenous siberian population. 19203299 - Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients w... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of pharmacology & pharmacotherapeutics Volume: 2 ISSN: 0976-5018 ISO Abbreviation: J Pharmacol Pharmacother Publication Date: 2011 Oct |
Date Detail:
|
Created Date: 2011-10-25 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101552113 Medline TA: J Pharmacol Pharmacother Country: India |
Other Details:
|
Languages: eng Pagination: 230-5 Citation Subset: - |
Affiliation:
|
Department of Pharmacology, P.D.U. Medical College, Rajkot, Gujarat, India. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Retreatodontics in maxillary lateral incisor with supernumerary root.
Next Document: Sugar substitutes: Health controversy over perceived benefits.